Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity

被引:60
作者
Romero, JR
Suzuka, SM
Nagel, RL
Fabry, ME
机构
[1] Albert Einstein Coll Med, Dept Med, Div Hematol, Montefiore Med Ctr, Bronx, NY 10461 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrine Hypertens, Boston, MA 02115 USA
关键词
D O I
10.1182/blood.V99.4.1103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide (NO), essential for maintaining vascular tone, is produced from arginine by nitric oxide synthase. Plasma arginine levels are low in sickle cell anemia, and it is reported here that low plasma arginine is also found in our sickle transgenic mouse model that expresses human alpha, human beta(S), and human beta(S-Antilles) and is homozygous for the mouse beta(major) deletion (S+S-Antilles). S+S-Antilles mice were supplemented with a 4-fold increase in arginine that was maintained for several months. Mean corpuscular hemoglobin concentration (MCHC) decreased and the percent high-density red cells was reduced. Deoxy K+ efflux is characteristic of red cells! in sickle cell disease and contributes to the disease process by increasing the MCHC and rendering the cells more susceptible to polymer formation. This flux versus the room air flux was reduced in S+S-Antilles red cells from an average value of 1.6 +/- 0.3 mmol per liter of red cells x minute (FU) in nonsupplemented mice to 0.9 +/- 0.3 FU (n = 4, P < .02, paired t test) in supplemented mice. In room air, V-max of the Ca++-activated K+ channel (Gardos) was reduced from 4.1 +/- 0.6 FU (off diet) to 2.6 +/- 0.4 FU (n = 7 and 8, P < .04, t test) in arginine-supplemented mice versus clotrimazole. In conclusion, the major mechanism by which arginine supplementation reduces red cell density (MCHC) in S+S-Antilles mice is by inhibiting the Ca++-activated K+ channel. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:1103 / 1108
页数:6
相关论文
共 29 条
[1]   Peroxynitrite formation and apoptosis in transgenic sickle cell mouse kidneys [J].
Bank, N ;
Kiroycheva, M ;
Ahmed, F ;
Anthony, GM ;
Fabry, ME ;
Nagel, RL ;
Singhal, PC .
KIDNEY INTERNATIONAL, 1998, 54 (05) :1520-1528
[2]   Renal nitric oxide synthases in transgenic sickle cell mice [J].
Bank, N ;
Aynedjian, HS ;
Qiu, JH ;
Osei, SY ;
Ahima, RS ;
Fabry, ME ;
Nagel, RL .
KIDNEY INTERNATIONAL, 1996, 50 (01) :184-189
[3]   Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: Relevance in the effects of red blood cells on platelet function [J].
Chen, LY ;
Mehta, JL .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (01) :57-61
[4]   TREATMENT WITH ORAL CLOTRIMAZOLE BLOCKS CA2+-ACTIVATED K+ TRANSPORT AND REVERSES ERYTHROCYTE DEHYDRATION IN TRANSGENIC SAD MICE - A MODEL FOR THERAPY OF SICKLE-CELL DISEASE [J].
DEFRANCESCHI, L ;
SAADANE, N ;
TRUDEL, M ;
ALPER, SL ;
BRUGNARA, C ;
BEUZARD, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) :1670-1676
[5]  
ENWONWU C O, 1989, Medical Science Research, V17, P997
[6]   NITROGEN-METABOLISM IN SICKLE-CELL-ANEMIA - FREE AMINO-ACIDS IN PLASMA AND URINE [J].
ENWONWU, CO ;
XU, XX ;
TURNER, E .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1990, 300 (06) :366-371
[7]   HIGH EXPRESSION OF HUMAN BETA-S-GLOBINS AND ALPHA-GLOBINS IN TRANSGENIC MICE - ERYTHROCYTE ABNORMALITIES, ORGAN DAMAGE, AND THE EFFECT OF HYPOXIA [J].
FABRY, ME ;
COSTANTINI, F ;
PACHNIS, A ;
SUZUKA, SM ;
BANK, N ;
AYNEDJIAN, HS ;
FACTOR, SM ;
NAGEL, RL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (24) :12155-12159
[8]  
FABRY ME, 1991, BLOOD, V78, P217
[9]  
FABRY ME, 1984, BLOOD, V64, P1042
[10]   Mechanisms of stroke in sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition [J].
French, JA ;
Kenny, D ;
Scott, JP ;
Hoffmann, RG ;
Wood, JD ;
Hudetz, AG ;
Hillery, CA .
BLOOD, 1997, 89 (12) :4591-4599